Sarepta Therapeutics, Inc. (SRPT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 300M 600M 900M Q4 '16: 5.4M Q1 '17: 16.3M Q2 '17: 35M Q3 '17: 46M Q4 '17: 57.3M Q1 '18: 64.6M Q2 '18: 73.5M Q3 '18: 78.5M Q4 '18: 84.4M Q1 '19: 87M Q2 '19: 94.7M Q3 '19: 99M Q4 '19: 100.1M Q1 '20: 113.7M Q2 '20: 137.4M Q3 '20: 143.9M Q4 '20: 145.1M Q1 '21: 146.9M Q2 '21: 164.1M Q3 '21: 189.4M Q4 '21: 201.5M Q1 '22: 210.8M Q2 '22: 233.5M Q3 '22: 230.3M Q4 '22: 258.4M Q1 '23: 253.5M Q2 '23: 261.2M Q3 '23: 331.8M Q4 '23: 396.8M Q1 '24: 413.5M Q2 '24: 362.9M Q3 '24: 467.2M Q4 '24: 658.4M Q1 '25: 744.9M Q2 '25: 611.1M Q3 '25: 399.4M Q4 '25: 442.9M Q1 '26: 730.8M Q2 '26: 401.3M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

-200M 0 200M 400M 600M Q1 '24: 308.9M Q2 '24: 316M Q3 '24: 338.1M Q4 '24: 505.9M Q1 '25: 474M Q2 '25: 360.6M Q3 '25: 219.3M Q4 '25: -29.1M Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25

Operating Income Quarterly

-450M -300M -150M 0 150M 300M 450M Q1 '10: -7.7M Q2 '10: -7.7M Q3 '10: -3.8M Q4 '10: -1.7M Q1 '11: -5.5M Q2 '11: -10.1M Q3 '11: -11.3M Q4 '11: -9M Q1 '12: -6.9M Q2 '12: -5.6M Q3 '12: -6.9M Q4 '12: -10.4M Q1 '13: -15.4M Q2 '13: -17.1M Q3 '13: -24.9M Q3 '13: -24.9M Q4 '13: -32.8M Q1 '14: -25.1M Q2 '14: -30.3M Q3 '14: -33.7M Q4 '14: -44.7M Q1 '15: -61.9M Q2 '15: -42.1M Q3 '15: -51.8M Q4 '15: -64.5M Q1 '16: -59.7M Q2 '16: -62.1M Q3 '16: -56.5M Q4 '16: -88.4M Q1 '17: -39.2M Q2 '17: -63.3M Q3 '17: -45.9M Q4 '17: -23.1M Q1 '18: -30.7M Q2 '18: -103.4M Q3 '18: -70.1M Q4 '18: -139.4M Q1 '19: -76.4M Q2 '19: -275.4M Q3 '19: -123.6M Q4 '19: -230.2M Q1 '20: -118M Q2 '20: -138.4M Q3 '20: -137.1M Q4 '20: -170.7M Q1 '21: -151.9M Q2 '21: -167.6M Q3 '21: -34.5M Q4 '21: -105.8M Q1 '22: -86.9M Q2 '22: -211.1M Q3 '22: -131.4M Q4 '22: -106.8M Q1 '23: -138.1M Q2 '23: -133.5M Q3 '23: -20.8M Q4 '23: 24.6M Q1 '24: 34.9M Q2 '24: -701K Q3 '24: 22.2M Q4 '24: 161.7M Q1 '25: -300.4M Q2 '25: 115.6M Q3 '25: -103.4M Q4 '25: -411.6M Q1 '26: 358.4M Q2 '26: 13.3M Q4 '10 Q1 '13 Q1 '15 Q2 '17 Q3 '19 Q4 '21 Q1 '24 Q2 '26

Net Income Quarterly

-600M -400M -200M 0 200M 400M 600M Q1 '10: -584K Q2 '10: -16.7M Q3 '10: -7.3M Q4 '10: -7.6M Q1 '11: 1.8M Q2 '11: 1.3M Q3 '11: -4M Q4 '11: -1.4M Q1 '12: -17.7M Q2 '12: 8M Q3 '12: -49.6M Q4 '12: -62.1M Q1 '13: -42.1M Q2 '13: -19.1M Q3 '13: -42M Q3 '13: -42M Q4 '13: -8.8M Q1 '14: -28.3M Q2 '14: -33.9M Q3 '14: -29.2M Q4 '14: -44.4M Q1 '15: -61.6M Q2 '15: -41.9M Q3 '15: -51.9M Q4 '15: -64.7M Q1 '16: -59.8M Q2 '16: -62.3M Q3 '16: -56.7M Q4 '16: -88.5M Q1 '17: 84.1M Q2 '17: -63M Q3 '17: -47.7M Q4 '17: -24M Q1 '18: -35.4M Q2 '18: -109.3M Q3 '18: -76.4M Q4 '18: -140.9M Q1 '19: -76.6M Q2 '19: -276.4M Q3 '19: -126.3M Q4 '19: -235.7M Q1 '20: -17.5M Q2 '20: -150.8M Q3 '20: -196.5M Q4 '20: -189.3M Q1 '21: -167.2M Q2 '21: -81.4M Q3 '21: -48.1M Q4 '21: -122M Q1 '22: -105M Q2 '22: -231.5M Q3 '22: -257.7M Q4 '22: -109.2M Q1 '23: -516.8M Q2 '23: -23.9M Q3 '23: -40.9M Q4 '23: 45.7M Q1 '24: 36.1M Q2 '24: 6.5M Q3 '24: 33.6M Q4 '24: 159M Q1 '25: -447.5M Q2 '25: 196.9M Q3 '25: -179.9M Q4 '25: -412.2M Q1 '26: 331M Q2 '26: -4.9M Q4 '10 Q1 '13 Q1 '15 Q2 '17 Q3 '19 Q4 '21 Q1 '24 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-750M -500M -250M 0 250M 500M 750M Q3 '10: -2.8M Q4 '10: -1.9M Q1 '11: -10.1M Q2 '11: -442K Q3 '11: -7.5M Q4 '11: -5.6M Q1 '12: -9M Q2 '12: -5.7M Q3 '12: -7.8M Q4 '12: -7.2M Q1 '13: -15M Q2 '13: -12M Q3 '13: -19.9M Q4 '13: -17.8M Q1 '14: -28.3M Q2 '14: -39.5M Q3 '14: -35.3M Q4 '14: -25.4M Q1 '15: -43.3M Q2 '15: -28.5M Q3 '15: -46.3M Q4 '15: -31.3M Q1 '16: -60.7M Q2 '16: -43.3M Q3 '16: -60.6M Q4 '16: -81.2M Q1 '17: -57.9M Q2 '17: -85.1M Q3 '17: -57.9M Q4 '17: -31.1M Q1 '18: -35.7M Q2 '18: -117.3M Q3 '18: -113.3M Q4 '18: -122.4M Q1 '19: -146.2M Q2 '19: -79M Q3 '19: -67.4M Q4 '19: -163.8M Q1 '20: 627.8M Q2 '20: -107.6M Q3 '20: -238.2M Q4 '20: -174.5M Q1 '21: -180.4M Q2 '21: -109.1M Q3 '21: -124.3M Q4 '21: -29.3M Q1 '22: -101.2M Q2 '22: -66.8M Q3 '22: -65M Q4 '22: -92.4M Q1 '23: -209.4M Q2 '23: -122.2M Q3 '23: -114.7M Q4 '23: -54.7M Q1 '24: -242.1M Q2 '24: 14.9M Q3 '24: -70.7M Q4 '24: 92M Q1 '25: -583.4M Q2 '25: 261.3M Q3 '25: -14.6M Q4 '25: 131.2M Q1 '26: -202.7M Q2 '26: 197.1M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Free Cash Flow Quarterly

-750M -500M -250M 0 250M 500M 750M Q3 '10: -3.1M Q4 '10: -2.1M Q1 '11: -10.3M Q2 '11: -891K Q3 '11: -7.8M Q4 '11: -5.9M Q1 '12: -9.1M Q2 '12: -5.8M Q3 '12: -7.8M Q4 '12: -7.2M Q1 '13: -15M Q2 '13: -12.4M Q3 '13: -21.2M Q4 '13: -18.4M Q1 '14: -33.6M Q2 '14: -44M Q3 '14: -47.8M Q4 '14: -28.6M Q1 '15: -43.9M Q2 '15: -29.2M Q3 '15: -47.5M Q4 '15: -32.4M Q1 '16: -61.9M Q2 '16: -43.7M Q3 '16: -61.5M Q4 '16: -84.1M Q1 '17: -62.4M Q2 '17: -88M Q3 '17: -58.7M Q4 '17: -35M Q1 '18: -47.8M Q2 '18: -126M Q3 '18: -133.4M Q4 '18: -142.6M Q1 '19: -162.5M Q2 '19: -95.7M Q3 '19: -76.9M Q4 '19: -181.1M Q1 '20: 618.7M Q2 '20: -126.8M Q3 '20: -263.5M Q4 '20: -203.1M Q1 '21: -201.5M Q2 '21: -115M Q3 '21: -133.6M Q4 '21: -31.5M Q1 '22: -106.7M Q2 '22: -75.9M Q3 '22: -73.2M Q4 '22: -100.4M Q1 '23: -218.9M Q2 '23: -140.1M Q3 '23: -144.4M Q4 '23: -73.7M Q1 '24: -274.5M Q2 '24: -14.2M Q3 '24: -108M Q4 '24: 54M Q1 '25: -627.1M Q2 '25: 229.5M Q3 '25: -37.5M Q4 '25: 127.6M Q1 '26: -204.8M Q2 '26: 196.5M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q2 '10: 110.4M Q1 '11: 121.3M Q2 '11: 23.2M Q3 '11: 22.6M Q4 '11: 22.6M Q1 '12: 135.7M Q2 '12: 22.7M Q3 '12: 22.8M Q4 '12: 26.3M Q1 '13: 31.8M Q2 '13: 32M Q3 '13: 33.9M Q3 '13: 33.9M Q1 '14: 37.8M Q2 '14: 39.9M Q3 '14: 41.1M Q1 '15: 41.3M Q2 '15: 41.4M Q3 '15: 41.6M Q1 '16: 45.7M Q2 '16: 46.2M Q3 '16: 48.3M Q1 '17: 56M Q2 '17: 55M Q3 '17: 61.3M Q4 '17: 64.3M Q1 '18: 64.6M Q2 '18: 65.5M Q3 '18: 66.2M Q1 '19: 71.7M Q2 '19: 74M Q3 '19: 74.2M Q1 '20: 76.4M Q2 '20: 78M Q3 '20: 78.5K Q1 '21: 79.5K Q2 '21: 79.7K Q3 '21: 79.9K Q1 '22: 87.3M Q2 '22: 87.5M Q3 '22: 87.6M Q1 '23: 88.2M Q2 '23: 88.7M Q3 '23: 88.9M Q1 '24: 99.1M Q2 '24: 99.1M Q3 '24: 100.4M Q1 '25: 97.4M Q2 '25: 106.6M Q3 '25: 100.2M Q1 '26: 121.9M Q2 '26: 105.4M Q2 '11 Q1 '13 Q1 '15 Q2 '17 Q2 '19 Q3 '21 Q1 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 -10.00 -5.00 0.00 5.00 10.00 15.00 Q1 '11: -1.72 Q2 '11: -1.51 Q3 '11: -1.62 Q4 '11: -0.16 Q1 '12: -0.31 Q2 '12: -0.02 Q3 '12: -2.01 Q4 '12: -4.31 Q1 '13: -5.50 Q2 '13: -6.45 Q3 '13: -5.52 Q2 '14: -3.07 Q3 '14: -2.54 Q4 '14: -3.39 Q1 '15: -4.13 Q2 '15: -4.29 Q3 '15: -4.83 Q4 '15: -5.19 Q1 '16: -5.01 Q2 '16: -5.35 Q3 '16: -5.28 Q4 '16: -5.46 Q1 '17: -2.65 Q2 '17: -2.45 Q3 '17: -2.05 Q4 '17: -0.80 Q1 '18: -2.85 Q2 '18: -3.37 Q3 '18: -3.74 Q4 '18: -5.42 Q1 '19: -5.94 Q2 '19: -8.01 Q3 '19: -8.56 Q4 '19: -9.67 Q1 '20: -8.83 Q2 '20: -7.02 Q3 '22: -8.22 Q4 '22: -8.03 Q1 '23: -12.69 Q2 '23: -10.31 Q3 '23: -7.83 Q4 '23: -5.80 Q1 '24: 0.43 Q2 '24: 0.77 Q3 '24: 1.57 Q4 '24: 2.28 Q1 '25: -2.69 Q2 '25: -0.87 Q3 '25: -3.01 Q4 '25: -8.44 Q1 '26: -0.96 Q2 '26: -2.90 Q3 '11 Q2 '13 Q3 '15 Q2 '17 Q1 '19 Q4 '22 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.